Press release from Companies
Publicerat: 2025-12-29 10:31:46
Copenhagen, 29 December 2025 – Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) today held its Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark
Today, the shareholders in Curasight passed the following resolutions at the Extraordinary General Meeting in accordance with the agenda:
1. Proposals from the Board of Directors
1.1 Authorisation to the Board of Directors to issue one or more convertible loan notes.
The general meeting adopted the proposal to authorise the Board of Directors to issue one or more convertible loan notes for the purpose of obtaining financing for the Company i.e. the convertible loan notes can be provided to entities providing funding. The Board of Directors plans on utilising the authorization to issue a convertible loan note to a third party lender backing the completed directed issue as detailed in the press release dated 12 December 2025 as part of the agreement with said third party investor.
Under the proposed authorisation, one of more convertible loan notes may be issued with a right of conversion into shares in the Company.
The number of shares to be converted may be adjusted in the event of capital changes and other comparable matters.
Consequently, article 5.3 of the Company’s Articles of Association will be amended as follows:
| 5.3 | Konvertibelt gældsbrev | Convertible Loan Note | |
| 5.3.1 | Selskabets bestyrelse er bemyndiget til af én eller flere gange i henhold til selskabslovens §155, jf. §169, at udstede et eller flere konvertible gældsbreve i Selskabet med ret for långiver til konvertering af sit lån til kapitalandele i Selskabet for op til i alt nominelt 125.313,30 kr. kapitalandele uden fortegningsret for de eksisterende kapitalejere i Selskabet til en kurs og fordeling, som fastlægges af bestyrelsen. Kursen kan være under markedskursen på tidspunktet for bestyrelsens beslutning. | The Company’s board of directors is authorised, pursuant to s. 155 of the Danish Companies Act, cf., s. 169 thereof, in one or several instances, to issue one or more convertible loan notes, which will entitle their holder(s) to convert their loans into shares in the Company for up to a total of nominally DKK 125,313.30 shares without pre-emption rights for the existing shareholders at a subscription price and allocation determined by the board of directors. The subscription price may be below the market price at the time of the decision of the board of directors. | |
| Samtidig er bestyrelsen bemyndiget til at foretage den dertil hørende forhøjelse af Selskabets aktiekapital ad en eller flere omgange med op til nominelt 125.313,30 kr., eller et andet beløb som følge af eventuel regulering af antallet af kapitalandele, som kan konverteres i tilfælde af reguleringer af selskabskapitalen og lignede forhold i henhold til de til enhver tid gældende vilkår for de udstedte konvertible gældsbreve. | The Company’s board of directors is also authorised to carry out any related share capital increases, in one or several instances, up to a total of nominally DKK 125,313.30 or such other amount as required following an adjustment of the numbers of shares to be converted in the event of capital changes and other comparable matters in accordance with the terms governing the issued convertible loan notes. | ||
| Bemyndigelsen løber frem til 29. december 2030. Aktier udstedt i henhold til bemyndigelsen i dette pkt. 5.3.1 skal indbetales fuldt ud ved gældskonvertering eller kontant indskud, være omsætningspapirer, skal lyde på navn og noteres på navn i Selskabets ejerbog. Der gælder samme indskrænkninger i aktiernes omsættelighed, som gælder for de eksisterende aktier og ingen aktionær er forpligtet til at lade aktier indløse helt eller delvist. | The authorization is valid until 29 December 2030. Shares issued pursuant to the authorization in this clause 5.3.1 must be paid up in full by conversion of debt or by cash payment, be negotiable instruments, be registered by name and be registered by the name of shareholders in the Company’s shareholders’ register. The same restrictions on transferability as those applying to the existing shares apply and no shareholder shall be obligated to have the shares redeemed partly or in full. | ||
| Bestyrelsen er bemyndiget til at genanvende eller genudstede eventuelle bortfaldne ikke udnyttede konvertible gældsbreve, forudsat at genanvendelsen eller genudstedelsen finder sted inden for de vilkår og tidsmæssige begrænsninger, der fremgår af bemyndigelsen. | The board of directors is authorized to reuse or reissue any lapsed, non-converted convertible loan note, provided that such reuse or reissuance observes the terms, and the expiration date set out in this authorization. |
1.2 Authorisation to the chairman of the meeting
The general meeting adopted a resolution to authorise the chairman of the meeting Ulrik Bangsbo Hansen, with full right of substitution, be authorised to apply for registration of the resolutions passed and to make any such amendments thereto as the Danish Business Authority or other authorities may require or request as a condition for registration or approval, as well as to continuously make and apply for registration of linguistic and other non-substantive adjustments to the Company’s Articles of Association.
***
The Company's new articles of association will be published on the Company’s website once they have been registered with the Danish Business Authority, and likewise, the minutes of the Annual General Meeting will also be made available on the website.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
